Jason Hoitt - 15 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Chief Patient Officer
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
4
Filing time
17 Mar 2026, 17:26:50 UTC
Previous filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hoitt Jason Chief Patient Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 17 Mar 2026 0001762572

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise +10,000 +251% $0.000000* 13,988 15 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise -10,000 -25% $0.000000* 30,000 15 Mar 2026 Common Stock 10,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported total includes an aggregate 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.